Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter

Human Pathology

Volumn 41, Issue 9, 2010, Pages 1330-1338

  Tan, Ke ^a   Kajino, Kazunori ^a   Momose, Shuji ^a   Masaoka, Akiko ^a   Sasahara, Keiichi ^a   Shiomi, Kazu ^a   Izumi, Hiroshi ^a   Abe, Masaaki ^a   Ohtsuji, Naomi ^a   Wang, Tegexibaiyin ^a   Hino, Okio ^a   Fujii, Hiroaki ^a,b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ageo Medical Laboratories   (Japan)

Author keywords

CpG island; Malignant mesothelioma; Mesothelin; Ms SNuPE; Promoter methylation

Indexed keywords

MESOTHELIN;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG CARCINOMA; LUNG LESION; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; METHYLATION; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; BASE SEQUENCE; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; EPITHELIOID CELLS; GENE EXPRESSION; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MOLECULAR SEQUENCE DATA; PLEURAL NEOPLASMS; PROMOTER REGIONS, GENETIC; SARCOMA;

EID: 77955919405     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.03.002     Document Type: Article

References (31)

1. Chang K., and Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesothelioma, and ovarian cancers Proc Natl Acad Sci U S A 93 1996 136 140
2. Kojima T., Oh-eda M., and Hattori K. Molecular cloning and expression of megakaryocyte potentiating factor cDNA J Biol Chem 270 1995 21984 21990
3. Chang K., Pastan I., and Willingham M.C. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas Int J Cancer 51 1992 548 554
4. Hough C.D., Sherman-Baust C.A., and Pizer E.S. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer Cancer Res 60 2000 6281 6287
5. Argani P., Iacobuzio-Donahue C., and Ryu B. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
6. Ordóñez N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma Mod Pathol 16 2003 192 197
7. Robinson B.W., Creaney J., and Lake R. Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 2003 1612 1616
8. Frierson H.F. Jr, Moskaluk C.A., and Powell S.M. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas Hum Pathol 34 2003 605 609
9. Cao D., Ji H., and Ronnett B.M. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary Int J Gynecol Pathol 24 2005 67 72
10. Hassan R., Laszik Z.G., Lerner M., Raffeld M., Postier R., and Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis Am J Clin Pathol 124 2005 838 845
11. Hassan R., Remaley A.T., and Sampson M.L. Detection and quantitation of serum mesothelin, a tumor marker for patients with 16 mesothelioma and ovarian cancer Clin Cancer Res 12 2006 447 453
12. Dainty L.A., Risinger J.I., and Morrison C. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma Gynecol Oncol 105 2007 563 570
13. Ho M., Bera T.K., and Willingham M.C. Mesothelin expression in human lung cancer Clin Cancer Res 13 2007 1571 1575
14. Shiomi K., Hagiwara Y., and Sonoue K. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma Clin Cancer Res 14 2008 1431 1437
15. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province Br J Ind Med 17 1960 260 271
16. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma N Engl J Med 353 2005 1591 1603
17. Weitzman S.A., and Graceffa P. Asbestos catalyzes hydroxyl and superoxide radical generation from hydrogen peroxide Arch Biochem Biophys 228 1984 373 376
18. Shatos M.A., Doherty J.M., Marsh J.P., and Mossman B.T. Prevention of asbestos-induced cell death in rat lung fibroblasts and alveolar macrophages by scavengers of active oxygen species Environ Res 44 1987 103 116
19. Toyokuni S. Mechanisms of asbestos-induced carcinogenesis Nagoya J Med Sci 71 2009 1 10
20. Zanella C.L., Posada J., Tritton T.R., and Mossman B.T. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor Cancer Res 56 1996 5334 5338
21. Moalli P.A., MacDonald J.L., Goodglick L.A., and Kane A.B. Acute injury and regeneration of the mesothelium in response to asbestos fibers Am J Pathol 128 1987 426 445
22. Kamp D.W., Israbian V.A., Preusen S.E., Zhang C.X., and Weitzman S.A. Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals Am J Physiol 268 1995 471 480
23. Musti M., Kettunen E., and Dragonieri S. Cytogenetic and molecular genetic changes in malignant mesothelioma Cancer Genet Cytogenet 170 2006 9 15
24. Destro A., Ceresoli G.L., and Baryshnikova E. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up Lung Cancer 59 2008 369 376
25. Hassan R., Bera T., and Pastan I. Mesothelin: a new target for immunotherapy Clin Cancer Res 10 2004 3937 3942
26. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci U S A 93 1996 9821 9826
27. Hucl T., Brody J.R., Gallmeier E., Iacobuzio-Donahue C.A., Farrance I.K., and Kern S.E. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif Cancer Res 67 2007 9055 9065
28. Kuppuswamy M.N., Hoffmann J.W., Spitzer C.K., Kasper S.G., Groce S.L., and Bajaj S.P. Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes Proc Natl Acad Sci U S A 88 1991 1143 1147
29. Gonzalgo M.L., and Jones P.A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE) Nucleic Acids Res 25 1997 2529 2531
30. Sato N., Maitra A., and Fukushima N. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma Cancer Res 15 2003 4158 4166
31. Cristaudo A., Foddis R., and Bonotti A. Polymorphisms the putative micro-RNA binding sites of mesothelin gene are associated with the serum levels of the mesothelin-related protein Occup Environ Med 67 2010 233 236